多参数MRI与靶向活检时代高级别前列腺上皮内瘤变的发病率、监测与自然史
结果显示iHGPIN检出率为7.0%,其中75%仅由系统活检发现;3年监测中csPCa仅见于MRI可疑病灶增大的患者。结论认为仅针对MRI靶点的活检策略将几乎消除iHGPIN检出,但会降低csPCa检出。
要点
- iHGPIN检出率7.0%,其中75%仅通过系统活检发现。
- 仅针对MRI靶点的活检策略将几乎消除iHGPIN检出,但降低csPCa检出。
- 3年活检应仅推荐于mpMRI可疑的患者。
核心结论
- 在此多参数MRI和靶向活检时代,iHGPIN患病率较低,归因于基于mpMRI选择活检对象及更易检出已存在的csPCa。
- 仅针对MRI靶点的活检策略将几乎消除iHGPIN检出,同时降低csPCa检出。
- 3年活检应仅对mpMRI可疑的男性进行。
研究设计与样本
- 活检方式为MRI-超声融合靶向活检联合系统活检。
- iHGPIN监测方案包括每6个月PSA、每年DRE、3年时mpMRI;重复活检主要推荐于mpMRI可疑者。
主要发现
- 628例活检中,良性、iHGPIN、前列腺癌分别为230例(33.7%)、48例(7.0%)、404例(59.2%)。
- 前列腺癌中低危和csPCa分别为140例(34.7%)和264例(65.3%)。
- iHGPIN仅由MRFTB、仅由SB、两者均检出分别为6例(12.5%)、36例(75%)、6例(12.5%)。
- 3年时32例mpMRI中,新发PI-RADS>2 ROI 4例,既有ROI增大或PI-RADS评分升高8例;其中9例接受活检,另3例因非可疑mpMRI活检。
- csPCa检出2例,均为ROI增大者。
关键数值与推荐
- iHGPIN监测:每6个月PSA评估,每年DRE,3年时mpMRI。
- 重复活检主要推荐于mpMRI可疑,定义为新发PI-RADS评分>2的ROI或既有ROI增大。
- 3年活检应仅对mpMRI可疑的男性进行。
临床怎么用
- 对于iHGPIN患者,应按照每6个月PSA、每年DRE、3年mpMRI的方案监测。
- 重复活检应主要针对mpMRI可疑(新发PI-RADS>2 ROI或既有ROI增大)的患者。
- 避免仅针对MRI靶点的活检策略,以免遗漏iHGPIN和csPCa。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the incidence of isolated high grade prostatic epithelial neoplasia (iHGPIN) following magnetic resonance imaging (MRI)-ultrasonography co-registration fusion targeted biopsy (MRFTB) coupled with systematic biopsy (SB) and to assess the detection rates of clinically significant prostate cancer (csPCa). PATIENTS AND METHODS: Beginning in June 2012, most patients at our institution underwent multiparametric MRI (mpMRI) before prostate biopsy. Biopsies were performed between June 2012 and October 2021. The surveillance protocol for iHGPIN included prostate-specific antigen assessment every 6 months, digital rectal examinations annually, and multiparametric MRI (mpMRI) at 3 years. Repeat biopsies were recommended primarily for suspicious mpMRI, defined as a new Prostate Imaging-Reporting and Data System (PI-RADS) score >2 region of interest (ROI) or an increase in size of the pre-existing ROI. RESULTS: Of the 628 biopsies, 230 (33.7%), 48 (7.0%), 404 (59.2%) were interpreted as benign, iHGPIN, or prostate cancer (PCa), respectively. Of these cancers 140 (34.7%) and 264 (65.3%) were low-risk PCa and csPCa, respectively. iHGPIN was detected in MRRFTB only, SB only, and both MRFRB + SB in six (12.5%) 36 (75%), and six patients (12.5%), respectively. Of the 32 MRI scans performed at 3 years, a new PI-RADS score >2 ROI or an increase in the size or PI-RADS score of a pre-existing ROI was observed in four and eight patients, respectively. Nine of these underwent biopsy. Three additional biopsies were performed on non-suspicious mpMRI. csPCa was detected in two patients, both with an enlarging ROI. CONCLUSION: To our knowledge, this is the first study examining the incidence, natural history, and subsequent csPCa detection rates for iHGPIN in the era of mpMRI and MRI targeted biopsy. The lower prevalence of iHGPIN is attributed to the selection of biopsy candidates based on mpMRI and an increased likelihood of detecting pre-existing csPCa. Our findings provide compelling evidence that biopsy strategies limited to MRI targets will almost eliminate iHGPIN detection while decreasing detection of csPCa. A 3-year biopsy should be performed only in men with suspicious mpMRI.
引用
- Eid N, Lepor H. Incidence, surveillance and natural history of high-grade prostatic epithelial neoplasia in the era of multiparametric MRI and targeted biopsy. BJU Int. 2025. PMID: 40275801. doi:10.1111/bju.16748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。